Peter H. Watson

36.5k citations

259 papers · 19.5k indexed · 5 hit papers · h-index 72

Impact in

Cancer Research top 0.1%
- Cancer, Hypoxia, and Metabolism
- Cancer Genomics and Diagnostics
Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Screening and Detection

Papers in

Cancer Research 67
- Cancer Genomics and Diagnostics 26
- Breast Cancer Treatment Studies 21
Oncology 78
- HER2/EGFR in Cancer Research 26

Co-authors: Leigh C. Murphy Etienne Leygue H. Lynch Hans F. A. Vasen Jukka‐Pekka Mecklin Adrian L. Harris Katy Milne Helmut Dotzlaw
Journals: Biopreservation and Biobanking (48 papers)Breast Cancer Research and Treatment (11 papers)Clinical Cancer Research (9 papers)Breast Cancer Research (8 papers)The Journal of Pathology (8 papers)
Partner nations: Canada United States United Kingdom

In The Last Decade

Peter H. Watson

252 papers receiving 19.2k citations

Hit Papers

5 papers align trajectories log scale

Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma 2011 · 1.5k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2011 Genome Research
2001 Journal of Clinical Oncology
2001 PubMed
2000 PubMed
1999 Gastroenterology

Peers

Countries citing papers authored by Peter H. Watson

Since Specialization

Citations

This map shows the geographic impact of Peter H. Watson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter H. Watson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter H. Watson more than expected).

Fields of papers citing papers by Peter H. Watson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter H. Watson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter H. Watson. The network helps show where Peter H. Watson may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Peter H. Watson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter H. Watson Line = papers co-authored together Peter H. Watson links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Principles of reproducible metabolite profiling of enriched lymphocytes in tumors and ascites from human ovarian cancer Nature Protocols ·Marisa K. Kilgour, Sarah MacPherson, Lauren G. Zacharias, SUNKai, Yair Baron, 拓哉国枝, Scott K. Parks, Ryan D. Sheldon, Russell G. Jones, Ralph J. DeBerardinis, Phineas T. Hamilton, Peter H. Watson, Julian J. Lum	2022	7
2	Building Research Support Capacity across Human Health Biobanks during the COVID-19 Pandemic Biomarker Insights ·Jennifer A. Byrne, Direk Ngamvasinont, Candace Carter, He-long Zhang, Stephen Braye, Peter H. Watson, Amanda Rush	2021	4
3	1-Methylnicotinamide is an immune regulatory metabolite in human ovarian cancer Science Advances ·Marisa K. Kilgour, Sarah MacPherson, Lauren G. Zacharias, Abigail E. Ellis, Ryan D. Sheldon, Alberto Lopes da Rosa, 陈兴都, 郭廷建, Gillian Carleton, Bertrand Allard, Julian Smazynski, Kelsey S. Williams, Peter H. Watson, John Stagg, Brad H. Nelson, Ralph J. DeBerardinis, Russell G. Jones, Phineas T. Hamilton, Julian J. Lum	2021	51
4	CD103 and Intratumoral Immune Response in Breast Cancer Clinical Cancer Research ·Zhiqiang Wang, Katy Milne, Heather Derocher, John R. Webb, Brad H. Nelson, Peter H. Watson	2016	130
5	Surveillance of the Tumor Mutanome by T Cells during Progression from Primary to Recurrent Ovarian Cancer Clinical Cancer Research ·Darin A. Wick, John R. Webb, Julie S. Nielsen, Spencer D. Martin, David R. Kroeger, Katy Milne, Mauro Castellarin, Kwame Twumasi‐Boateng, Peter H. Watson, Robert A. Holt, Brad H. Nelson	2013	126
6	CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27− Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian Cancer Clinical Cancer Research ·Julie S. Nielsen, Rob A. Sahota, Katy Milne, Sara E. Kost, Nancy J. Nesslinger, Peter H. Watson, Brad H. Nelson	2012	418
7	Oncostatin M suppresses oestrogen receptor-α expression and is associated with poor outcome in human breast cancer Endocrine Related Cancer ·Nathaniel R. West, Leigh C. Murphy, Peter H. Watson	2012	59
8	The autophagy protein LC3A correlates with hypoxia and is a prognostic marker of patient survival in clear cell ovarian cancer The Journal of Pathology ·Bernadina Amantino, Katelin N. Townsend, 燕建田, AMANDA CHABAN, Nathaniel R. West, Chatkaew Pongmala, Steve E. Kalloger, Michael S. Anglesio, Sharon M. Gorski, Peter H. Watson, C. Blake Gilks, David G. Huntsman, Julian J. Lum	2012	44
9	Sex differences in resident immune cell phenotype underlie more efficient acute inflammatory responses in female mice Blood ·Ramona S. Scotland, Melanie Stables, Shimona Madalli, Peter H. Watson, Derek W. Gilroy	2011	235
10	A phosphorylation code for oestrogen receptor-α predicts clinical outcome to endocrine therapy in breast cancer Endocrine Related Cancer ·Georgios Skliris, Zoann Nugent, Brian G. Rowan, Carla R. Penner, Peter H. Watson, Leigh C. Murphy	2010	39
11	Clinicopathologic factors of the recurrent tumor predict outcome in patients with ipsilateral breast tumor recurrence Cancer ·Valérie Panet-Raymond, Pauline T. Truong, Cheryl Alexander, Mary Lesperance, Rachel McDonald, Peter H. Watson	2010	21
12	Estrogen Receptor Alpha Phosphorylated at Tyrosine 537 is Associated with Poor Clinical Outcome in Breast Cancer Patients Treated with Tamoxifen Hormones and Cancer ·Georgios Skliris, Zoann Nugent, Peter H. Watson, Leigh C. Murphy	2010	13
13	Expression of small breast epithelial mucin (SBEM) protein in tissue microarrays (TMAs) of primary invasive breast cancers Histopathology ·G. Skliris, Florent Hubé, James Dike, Mark M. Mutawe, Carla Penner, Peter H. Watson, Leigh C. Murphy, Etienne Leygue, Yvonne Myal	2008	32
14	CD8+ T Cells Induce Complete Regression of Advanced Ovarian Cancers by an Interleukin (IL)-2/IL-15–Dependent Mechanism Clinical Cancer Research ·G. N. Ivanov, Erika M. Wall, Katy Milne, Patty Theiss, Peter H. Watson, Brad H. Nelson	2007	16
15	Spontaneous Mammary Tumors Differ Widely in Their Inherent Sensitivity to Adoptively Transferred T Cells Cancer Research ·Erika M. Wall, Katy Milne, Yusuke Okude, Peter H. Watson, Patty Theiss, Brad H. Nelson	2007	25
16	BRCA1 and c-Myc Associate to Transcriptionally Repress Psoriasin, a DNA Damage–Inducible Gene Cancer Research ·Richard D. Kennedy, Julia J. Gorski, Jennifer E. Quinn, Gail E. Stewart, Colin R. James, Miguel Marin-Rodero, Karl Mulligan, Ethan Emberley, T F Lioe, Patrick J. Morrison, Paul B. Mullan, George Reid, Patrick G. Johnston, Peter H. Watson, D. Paul Harkin	2005	71
17	Angelman syndrome phenotype associated with mutations in MECP2. Journal of Medical Genetics ·Peter H. Watson, A. Renoux, Sarah Ramsden, Margaret Barrow, M Super, Briedgeen Kerr, Jill Clayton‐Smith	2001	1
18	Regulation of growth and tumorigenicity of breast cancer cells by the low molecular weight GTPase Rad and nm23. PubMed ·Yu‐Hua Tseng, David Vicent, Jianhua Zhu, Yulian Niu, Adewale Adeyinka, Julie S. Moyers, Peter H. Watson, C. Ronald Kahn	2001	76
19	Somatic mutation in the MECP2 gene may be a cause of non-lethal neurodevelopmental diosrder in males. The Lancet ·Jill Clayton‐Smith, Peter H. Watson, Sarah Ramsden, Graeme C. Black	2000	6
20	The Eleventh and Twelfth Seasons of Excavations at Pella (Tabaqat Fahl) 1989-1990 UCL Discovery (University College London) ·Klaus Strunk, (unknown), José Ignacio Llaguno Musons, Navarro Ricopa, Peter H. Watson, John Musau, (unknown), F Dengler, W.L. Alwis, (unknown), (unknown)	1993	4

About Peter H. Watson

Peter H. Watson is a scholar working on Cancer Research, Oncology, Genetics, Public Health, Environmental and Occupational Health and Molecular Biology, having authored 259 papers that have together received 19.5k indexed citations. Recurring topics across this work include Ethics in Clinical Research (51 papers), Estrogen and related hormone effects (46 papers), Biomedical Ethics and Regulation (28 papers), Cancer Genomics and Diagnostics (26 papers), HER2/EGFR in Cancer Research (26 papers), Health Systems, Economic Evaluations, Quality of Life (23 papers), Breast Cancer Treatment Studies (21 papers) and S100 Proteins and Annexins (21 papers). The work is most often cited by research in Cancer Research (5.0k citations), Oncology (7.2k citations), Pathology and Forensic Medicine (2.6k citations), Immunology (2.9k citations) and Molecular Biology (9.1k citations). Peter H. Watson has collaborated with scholars based in Canada, United States and United Kingdom. Frequent co-authors include Leigh C. Murphy, Etienne Leygue, H. Lynch, Hans F. A. Vasen, Jukka‐Pekka Mecklin, Adrian L. Harris, Katy Milne, Helmut Dotzlaw, Peter J. Ratcliffe and Brad H. Nelson. Their work appears in journals such as Biopreservation and Biobanking, Breast Cancer Research and Treatment, Clinical Cancer Research, Breast Cancer Research and The Journal of Pathology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact